A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression

Trial Profile

A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Cediranib (Primary) ; Sunitinib (Primary)
  • Indications Alveolar soft part sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Aug 2017 Planned End Date changed from 28 Apr 2018 to 15 Jun 2018.
    • 04 May 2017 Planned End Date changed from 28 Apr 2017 to 28 Apr 2018.
    • 04 May 2017 Planned primary completion date changed from 28 Apr 2017 to 28 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top